Teva Pharma (TEVA) Tops Q1 EPS by 4c, Revenues Miss; Offers FY21 EPS/Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. INSP
9. HNGE
10. SPY

Go back to Teva Pharma (TEVA) Tops Q1 EPS by 4c, Revenues Miss; Offers FY21 EPS/Revenue Guidance

Teva Reports First Quarter 2021 Financial Results

April 28, 2021 7:00 AM EDT

Revenues of $4.0 billion GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.63 Cash flow used in operating activities of $405 million Free cash flow of $59 million Full year 2021 business outlook reaffirmed: Net revenues of $16.4-16.8 billion EBITDA of $4.8 - $5.1 billion EPS of $2.50 - $2.70 Free cash flow of $2.0 - $2.3 billion

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31,... More